Germany – Pharmaceutical products

Original title (German): Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Melatonin, ausgenommen Darreichungsform 2 mg Retardtabletten, ATC N05CH01

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

October 05, 2026
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Open house drug discount contracts Melatonin, excluding 2 mg prolonged-release tablets, ATC N05CH01

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedOctober 17, 2024
Procurement stageActive solicitation
Response dueOctober 05, 2026
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedSeptember 20, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient budesonide, ATC A07EA06, for the period 01.03.2026 - 29.02.2028 (plus extension option of 1 x 12 months)
Germany – Pharmaceutical products
Germany – Pharmaceutical products
Germany – Pharmaceutical products
Germany – Pharmaceutical products
Germany – Pharmaceutical products
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient doravirine, ATC J05AG06, for the period 01.12.2025 - 30.11.2027

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.